摘要
Abstract
Objective To investigate the clinical effect of fluticasone propionate aerosol (Flixotide) versus budesonide/formoterol powder for inhalation (Symbicort Turbuhaler) in the treatment of children with mild-to-moderate asthma,as well as the cost of purchasing controlled drugs.Methods A total of 100 children aged 4 14 years who visited the outpatient service,met the diagnostic criteria for mild-to-moderate asthma,and achieved symptom remission after treatment were enrolled and randomly divi-ded into two groups,with 50 children in each group.The children in the treatment group were given Flixotide,and those in the control group were given Symbicort Turbuhaler.All children were followed up for 1 year,and the two groups were compared in terms of the maintenance time of no wheezing symptoms,number of emergency treatments,peak expiratory flow (PEF) before and after treatment,and cost of controlled drugs.Results There were no significant differences between the control group and the treatment group in the maintenance time of no wheezing symptoms,number of emergency treatments,and PEF before and after treatment (P＞0.05);however,there was a significant difference in the cost of controlled drugs between the two groups (t =-17.57,P＜0.05).Conclusion There is no significant difference in the clinical effect between Flixotide and Symbicort Turbuhaler in the treatment of children with mild-to-moderate asthma,but Flixotide has a lower cost than Symbicort Turbuhaler.关键词
哮喘/丙酸氟替卡松气雾剂/布地奈德/福莫特罗/治疗结果Key words
asthma/fluticasone propionate aerosol/budesonide/formoterol/treatment outcome分类
医药卫生
